Drug Type Small molecule drug |
Synonyms Aclatonium napadisilate (JAN), SKF-100916-J, TM-723 + [1] |
Target |
Action agonists |
Mechanism mAChRs agonists(Muscarinic acetylcholine receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (01 Jan 1981), |
Regulation- |
Molecular FormulaC30H46N2O14S2 |
InChIKeyHELVYVGHOJPCEV-UHFFFAOYSA-L |
CAS Registry55077-30-0 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Gastrointestinal motility disorder | Japan | 01 Jan 1981 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Biliary Dyskinesia | Phase 1 | China | 22 Dec 2017 | |
| Feeding and Eating Disorders | Phase 1 | China | 22 Dec 2017 | |
| Gastritis | Phase 1 | China | 22 Dec 2017 | |
| Nausea | Phase 1 | China | 22 Dec 2017 | |
| Vomiting | Phase 1 | China | 22 Dec 2017 |





